This Is AuburnElectronic Theses and Dissertations

Show simple item record

Plasmonic nanomaterials for label-free biosensor towards next-generation point-of-care immunoassay


Metadata FieldValueLanguage
dc.contributor.advisorChen, Pengyu
dc.contributor.authorHe, Jiacheng
dc.date.accessioned2021-11-12T14:26:15Z
dc.date.available2021-11-12T14:26:15Z
dc.date.issued2021-11-12
dc.identifier.urihttps://etd.auburn.edu//handle/10415/7957
dc.description.abstractCytokines, a broad category of low molecular weight signaling proteins, are key immune modulators for cell-based immune response. An abnormal level of cytokine can lead to acute/chronic inflammation, multiple organ failure, or even death. The current “gold standard” method for cytokine quantification is enzyme-linked immunosorbent assay (ELISA), which involves tedious labeling and washing process. In a current clinical laboratory setting, a minimum assay time of 3-8 h is required for simplex cytokine measurement. Considering a detrimental acute inflammation, characterized by the unregulated and increased level of cytokines, a personalized cytokine-blockade treatment needs to be delivered in time based on the individual’s transient immune status. In this regard, an unmet need is developing a next-generation multiplexed immunoassay allowing rapid cytokine analysis with sufficient sensitivity. Localized surface plasmon resonance (LSPR)-based immunoassay that exploits attractive optical properties of plasmonic nanomaterials is a promising candidate to bridge such a gap. In this dissertation, we demonstrated the development of point-of-care nanoplasmonic immunoassay from three aspects. Firstly, we developed a scalable manufacturing method for the parallel fabrication of multiplexed immunoassay by using the weasel hair-enabled calligraphy technique. Secondly, we improved the sensing performance of the current LSPR immunoassay by engineering conventional antibodies and adopting a new LSPR sensing methodology, i.e., digital LSPR. Lastly, we demonstrated the practical use of our label-free LSPR immunoassay to characterize the T cell responses to a type 2 diabetes biomarker, human islet amyloid polypeptide (hIAPP) with differing aggregation stages. Together, we demonstrated the developed LSPR immunoassays can be a promising tool for patient immune status monitoring and cellular functional analysis.en_US
dc.rightsEMBARGO_GLOBALen_US
dc.subjectMaterials Engineeringen_US
dc.titlePlasmonic nanomaterials for label-free biosensor towards next-generation point-of-care immunoassayen_US
dc.typePhD Dissertationen_US
dc.embargo.lengthMONTHS_WITHHELD:12en_US
dc.embargo.statusEMBARGOEDen_US
dc.embargo.enddate2022-11-12en_US
dc.contributor.committeeCheng, Zhongyang
dc.contributor.committeeKim, Dong-Joo
dc.contributor.committeeEasley, Christopher
dc.contributor.committeeLi, Feng
dc.creator.orcidhttps://orcid.org/0000-0002-1940-4262en_US

Files in this item

Show simple item record